<style face="normal" font="default" size="100%">782-F Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102: an interim report of the single-agent cohort in Phase I clinical trial</style>

Drupal-HighWire